Mark L. Levitt
Impact in
- Oncology top 5%
- Cancer-related Molecular Pathways
- Lung Cancer Research Studies
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Occupational and environmental lung diseases
Papers in
- Oncology 18
- Lung Cancer Research Studies 9
- HER2/EGFR in Cancer Research 3
- Cancer-related Molecular Pathways 2
-
- Lung Cancer Treatments and Mutations 8
- Lung Cancer Diagnosis and Treatment 5
- Co-authors
- Adi F. Gazdar (2 shared papers)John Dorrance Minna (2 shared papers)Michelle Vinocour (1 shared paper)Richard K. Rosenberg (1 shared paper)Michael J. Birrer (1 shared paper)Marion M. Nau (1 shared paper)Takashi Takahashi (1 shared paper)Itsuo Chiba (1 shared paper)
- Journals
- Lung Cancer (8 papers)Cancer Chemotherapy and Pharmacology (2 papers)Investigational New Drugs (2 papers)Journal of Leukocyte Biology (2 papers)Journal of Thoracic Oncology (1 paper)
- Partner nations
- United StatesIsraelChina
In The Last Decade
Mark L. Levitt
38 papers receiving 1.9k citations
Mark L. Levitt's Hit Papers
Peers
Comparison fields: 5 of 80
- Oncology 901
- Pulmonary and Respiratory Medicine 446
- Cancer Research 136
- Otorhinolaryngology 32
- Molecular Biology 357
Countries citing papers authored by Mark L. Levitt
This map shows the geographic impact of Mark L. Levitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark L. Levitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark L. Levitt more than expected).
Fields of papers citing papers by Mark L. Levitt
This network shows the impact of papers produced by Mark L. Levitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark L. Levitt. The network helps show where Mark L. Levitt may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark L. Levitt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | p53: A Frequent Target for Genetic Abnormalities in Lung Cancer Hit paper breakdown → | 1989 | 1069 |
| 2 | 2006 | 141 | |
| 3 | 1989 | 130 | |
| 4 | 1999 | 72 | |
| 5 | Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. | 1976 | 65 |
| 6 | 1999 | 49 | |
| 7 | 1995 | 43 | |
| 8 | 1999 | 42 | |
| 9 | 2007 | 35 | |
| 10 | 1995 | 26 | |
| 11 | 2003 | 25 | |
| 12 | 1999 | 24 | |
| 13 | 1998 | 23 | |
| 14 | Sequential methotrexate and 5-FU in the treatment of colorectal cancer. | 1982 | 22 |
| 15 | 1999 | 22 | |
| 16 | 2022 | 22 | |
| 17 | Oat cell carcinoma of the lung: CNS metastases in spite of prophylactic brain irradiation. | 1978 | 19 |
| 18 | 1997 | 19 | |
| 19 | 1998 | 16 | |
| 20 | 1998 | 15 |
About Mark L. Levitt
Mark L. Levitt is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Infectious Diseases and Genetics, having authored 41 papers that have together received 2k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers), Cell death mechanisms and regulation (7 papers), Lung Cancer Diagnosis and Treatment (5 papers), HER2/EGFR in Cancer Research (3 papers), Sphingolipid Metabolism and Signaling (2 papers), COVID-19 Clinical Research Studies (2 papers) and Cancer-related Molecular Pathways (2 papers). The work is most often cited by research in Oncology (901 citations), Pulmonary and Respiratory Medicine (446 citations), Cancer Research (136 citations), Otorhinolaryngology (32 citations) and Molecular Biology (357 citations). Mark L. Levitt has collaborated with scholars based in United States, Israel and China. Frequent co-authors include Adi F. Gazdar, John Dorrance Minna, Michelle Vinocour, Richard K. Rosenberg, Michael J. Birrer, Marion M. Nau, Takashi Takahashi, Itsuo Chiba, Harvey Ira Pass and Patrick P. Koty. Their work appears in journals such as Lung Cancer, Cancer Chemotherapy and Pharmacology, Investigational New Drugs, Journal of Leukocyte Biology and Journal of Thoracic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.